Are we seeing any breakthroughs in the treatment of AML?
Why do charities need to keep funding research into leukemia and blood cancer in general?
BTK inhibition in primary CNS lymphoma
Deacetylase inhibitors: a novel class of drugs for immune system malignancies
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia